CAS: 1708118-13-1

Impurity Everolimus Impurity Stability Light and temperature Sensitive Applications Everolimus Retroaldol Degradation Product is an impurity of Everolimus (E945400). Everolimus is a derivative of Rapamycin. Everolimus inhibits cytokine-mediated lymphocyte proliferation. Everolimus Impurity D References Dumont, F.J., et al.: Curr. Opin. Invest. Drugs, 2, 1220 (2001), Kovarik, J. M., et al.: Clin. Pharmacol. Ther., 69, 48 (2001), Nashan, B., et al.: Ther. Drug Monit., 24, 53 (2002),

Everolimus is a drug that is used in the treatment of certain cancers. It acts by binding to the cytosolic protein receptor known as the mammalian target of rapamycin (mTOR). This binding causes the inhibition of mTOR. Everolimus is converted by enzymes into a number of metabolites, including the retroaldol degradation product. The retroaldol degradation product has been shown to bind to ion channels and inhibit their activity. It is also a ligand for several receptors, such as the peptide growth hormone releasing factor (GHRF) receptor.